Senseonics Announces Favorable Outcome of FDA Advisory Committee on the Eversense System

By |2018-06-21T14:59:24+00:00April 2nd, 2018|CGM, Senseonics|

GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced a favorable outcome of the U.S. Food and Drug Administration (FDA) Clinical Chemistry and Clinical Toxicology Devices meeting on the Eversense system. [...]

Webinar: Senseonics Science & Education Series

By |2017-12-04T17:05:55+00:00November 27th, 2017|Science & Technology, Senseonics|

You are invited to  the first webinar in the Senseonics Science & Education Series presented by Director of Engineering, Dr. Andrew (Andy) DeHennis on Fluorescence Technology on Tuesday, Dec 19, 2017 10:00 AM EST. Fluorescence-based sensing technology offers an alternative to enzyme-based, electrochemical methods of sensing. In this webinar you will learn how this technology [...]

David Edelman visited Senseonics

By |2017-12-04T17:03:24+00:00November 14th, 2017|CGM, Senseonics|

Senseonics welcomed David Edelman from Diabetes Daily yesterday. David gave a great presentation on the importance of peer support communities for people with diabetes and their care allies. Also discussed was Senseonics’ advanced CGM technology and how it is designed to transform the CGM user experience. David talked about the importance of CGM and its [...]